Overview


Antibiotics can stop the growth and death of many kinds of infections. Antibiotics may be used to prevent infection from happening in certain cases, such as before surgery. You can give antibiotics in many ways. These include oral - tablets or capsules, liquids, and liquids to treat mild to moderate infections. Topical - Creams, lotions sprays, drops, or sprays that treat skin infections. For more severe infections, injections can be given directly into the bloodstream or muscle. Antibiotics were first discovered in the 20th century to treat multiple bacterial infections such as wound infections, bacterial pneumonia, and tuberculosis. The broad spectrum of antibiotics is made up of powerful drugs that are used to treat bacterial infections. Patients with bacterial infections are prescribed antibiotics to be taken by mouth. Prosthetic joint infections are a common complication after joint replacements. Extended oral antibiotics can reduce the incidence of these infections. Antibiotics are an antimicrobial substance that fights against bacterial infections, rarely with protozoan infections, but not viruses. Prosthetic joint infections can be prevented or controlled with extended oral antibiotics. However, the timing of delivery is controversial to maximize patient outcomes. Peri-prosthetic injury (PJI) is another name for prosthetic joint infections. This refers to an infection that affects adjacent tissues as well as the joint prosthesis.

Prosthetic joint infections are a common cause of implant failure following joint replacement surgeries. They can be very costly for the global healthcare system and can lead to significant psychological and physical morbidity. Prosthetic joint infections (PJI), which occur in the first year after surgery, are caused by the introduction of microorganisms into the prosthetic tissue or prosthesis. Extended oral antibiotics are effective in reducing the incidence of prosthetic joint infection. The prosthetic joint infection rate in high-risk patients treated with antibiotics was lower than that in patients at low risk. Prosthetic joint infections are one of the most common complications after joint replacement surgery. Extended oral antibiotics were found to be effective in reducing this rate. Antibiotics are antimicrobial drug that is effective in fighting bacterial infections, rarely protozoan infections, and rarely viral infections. Due to increasing numbers of total joint arthroplasties (hip, knee, and TKA) arthroplasty), and cases of prosthetic joint infections, extended oral antibiotics will be in high demand. Prosthetic joint infections are a common treatment option. However, there are many questions about the timing and route of administration to ensure the best possible patient outcomes.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Extended Oral Antibiotics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Extended Oral Antibiotics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Arrevus, Melinta Therapeutics Inc.
  • Nabriva Therapeutics plc
  • Peptilogics Inc.
  • elephus Medical LLC

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Drug Type

  • Rifampin
  • Ciprofloxacin
  • Penicillin
  • Ampicillin
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Extended Oral Antibiotics Market By Drug Type, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Extended Oral Antibiotics Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Drug Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Extended Oral Antibiotics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Extended Oral Antibiotics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Drug Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Drug Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Extended Oral Antibiotics Market, By Drug Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Rifampin
        2. Ciprofloxacin
        3. Penicillin
        4. Ampicillin
        5. Others

  • 8.   Extended Oral Antibiotics Market, By Distribution Channel Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
        4. Others

  • 9.   North America Extended Oral Antibiotics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 10.   Latin America Extended Oral Antibiotics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 11.   Europe Extended Oral Antibiotics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 12.   Asia Pacific Extended Oral Antibiotics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 13.   Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Arrevus, Melinta Therapeutics Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Nabriva Therapeutics plc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Peptilogics Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. elephus Medical LLC
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                   administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients